Jeremiah Shepard

Analysts led by Jeremiah Shepard at Credit Suisse assumed coverage for the SMID biotech stocks listed below. The following includeds highlights from the analysts along with the current ratings and price targets: Alder Biopharmaceuticals Inc (NASDAQ: ALDR) – Outperform, target price $36...

Credit Suisse commented on Sarepta Therapeutics Inc (NASDAQ: SRPT) ahead of an FDA workshop on Friday titled "Measuring Dystrophin in Dystrophinopathy Patients and Interpreting the Data." Analysts led by Jeremiah Shepard thought the meeting would "highlight the pros and cons of...

Credit Suisse on Thursday issued a report on Pharmacyclics, Inc. (NASDAQ: PCYC) a day after the company soared 17 percent following acquisition rumors. Credit Suisse downgraded Pharmacyclics from Outperform to Neutral and raised its price target from $163 to $233. A report  issued by...